Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

Promega's Cookie Policy

We use cookies and similar technologies to make our website work, run analytics, improve our website, and show you personalized content and advertising. Some of these cookies are essential for our website to work. For others, we won’t set them unless you accept them. To find out more about cookies and how to manage cookies, read our Cookie Policy.

RAS TDD Resource Page

Resources and featured presentations for kinase biology, protein degradation, and more.

Welcome to our resource page for the 2nd RAS Targeted Drug Development (TDD) Summit. Because we won’t be able to meet you in person, explore this page for information and resources about kinase biology, target engagement, protein degradation and more. Learn how we can support your research with our products and technologies.

matt robers A Comprehensive Live-Cell Target Engagement Approach for the RAS-RAF-MEK-ERK Pathway

Presented by Matt Robers, Senior Research Scientist, Promega Corporation

As a driver of tumorigenesis in a variety of cell types, the RAS-mapk pathway has been the subject of concerted drug discovery efforts for decades. Here we will present the use of NanoBRET™-TE to quantify live cell target engagement to all of the described drug binding sites within the RAS-RAF-MEK-ERK pathway. With this method, we can observe the impact of oncogenic KRAS (G12C) on engagement potency on downstream effectors including BRAF. We have also developed a pan-KRAS NanoBRET™ tracer that has the capacity to detect a variety of orthosteric and allosteric engagement mechanisms at this challenging target, previously deemed “undruggable”.

  • Development of a pan-RAS target engagement assay for querying multiple inhibitory mechanisms
  • Real-time analysis of engagement and protein-protein interactions at RAS and its effector proteins
  • The landscape of engagement selectivity and drug residence time for the mapk pathway in the presence of active KRAS

Resources for Drug Discovery

Small-Molecule Drug Discovery

Our comprehensive collection of products and services for small-molecule drug discovery will help to accelerate your workflow.

Learn More

Assay Development and Services

Let our team of experts guide you through customized solutions for your drug discovery workflow, with application-specific designs and and automation options.

Learn More

Protein Degradation

Study protein degradation in live cells from compound cell permeability and E3 ligase engagement to target degradation. Learn about the comprehensive selection of CRISPR-edited cell line pools and clones to facilitate studying popular protein degradation targets that Promega has to offer.

protein degradation crispr knock-in

Kinase Biology

Promega offers biochemical assays for inhibitor screening, kinase-ligand binding assays in live cells and custom kinase assay services. Our bioluminescent assays are available to query the ability of compounds to bind or inhibit kinases in biochemical and cellular formats.

kinase biology

CRISPR Cas9 Knock-in Tagging

CRISPR/Cas9 knock-in tagging offers a convenient method to study endogenous biology, without the drawbacks of overexpression methods. Promega offers a comprehensive selection of CRISPR-edited cell line pools and clones for popular drug targets and cell backgrounds.

CRISPR cas9 knock-in tagging

Target Engagement

Measure compound-target residence time and screen inhibitor panels with sensitive, live-cell binding assays that use an energy transfer technique to measure molecular proximity.

kinase target engagement

Cell Health

Using high-throughput assays from Promega, you can perform comparative analysis by multiplexing assays with other measures of cell health, such as apoptosis and autophagy. Check out our complete offering of cell health screening assays.

cell health

Looking for more information about the 2nd RAS-Targeted Drug Development Summit?

Visit the Virtual Event Page